Table 2.
Patient characteristic in SBISC cohort.
| Variables | Total n = 364 | PLT < 100 × 109/L n = 116 | PLT ≥ 100 × 109/L n = 248 | P |
|---|---|---|---|---|
| Age, Median [IQR] | 60.0 [45.0;73.0] | 59.0 [42.5;74.0] | 60.5 [46.0;73.0] | 0.783 |
| Gender | 0.945 | |||
| Male, n (%) | 236 (64.8) | 76 (65.5) | 160 (64.5) | |
| Female, n (%) | 129 (35.2) | 41 (34.5) | 88 (35.5) | |
| Medical conditions | ||||
| Myocardial infarct, n (%) | 17 (4.67) | 4 (3.45) | 13 (5.24) | 0.625 |
| Congestive heart failure, n (%) | 157 (43.1) | 44 (37.9) | 113 (45.6) | 0.209 |
| Chronic pulmonary disease, n (%) | 44 (12.1) | 18 (15.5) | 26 (10.5) | 0.179 |
| Mild liver disease, n (%) | 25 (6.87) | 17 (14.7) | 8 (3.23) | <0.001 |
| Diabetes, n (%) | 88 (24.2) | 21 (18.1) | 67 (27.0) | 0.063 |
| Renal disease, n (%) | 30 (8.24) | 9 (7.76) | 21 (8.47) | 0.837 |
| Malignant cancer, n (%) | 105 (28.8) | 38 (32.8) | 67 (27.0) | 0.264 |
| CCI, Mean (SD) | 4.80 (3.15) | 4.79 (3.49) | 4.80 (2.98) | 0.987 |
| Primary Infection source | ||||
| Lung, n (%) | 148 (40.7) | 43 (37.1) | 105 (42.3) | 0.401 |
| Abdomen, n (%) | 52 (14.3) | 25 (21.6) | 27 (10.9) | 0.011 |
| Urinary, n (%) | 34 (9.3) | 8 (6.9) | 26 (10.5) | 0.367 |
| Skin and soft tissue, n (%) | 13 (3.6) | 8 (6.9) | 5 (2.0) | 0.030 |
| Central nervous system, n (%) | 6 (1.6) | 2 (1.7) | 4 (1.6) | 1.000 |
| Endocardium, n (%) | 2 (0.6) | 1 (0.9) | 1 (0.4) | 0.536 |
| Intravascular devices, n (%) | 50 (13.7) | 16 (13.8) | 34 (13.7) | 1.000 |
| other, n (%) | 7 (1.92) | 0 (0.0) | 7 (2.8) | 0.102 |
| Unknown, n (%) | 105 (28.8) | 35 (30.2) | 70 (28.2) | 0.797 |
| Lab value, median [IQR] | ||||
| WBC, ×109/L | 12.2 [7.54;17.6] | 10.7 [3.43;16.7] | 12.6 [8.85;17.9] | 0.001 |
| PT, second | 15.4[13.2;17.6] | 15.4[13.9;15.4] | 14.4[12.9;16.9] | <0.001 |
| APTT, second | 34.8[29.0;44.6] | 41.6 [33.0;48.6] | 32.0[28.3;40.8] | <0.001 |
| Bilirubin, mg/dl | 0.9 [0.5; 2.0] | 1.6 [0.8; 3.4] | 0.8 [0.5; 1.4] | <0.001 |
| Creatinine, mg/dl | 0.9 [0.6; 1.5] | 1.0 [0.7;1.9] | 0.8 [0.6;1.4] | 0.005 |
| Microorganism | 0.025 | |||
| Enterococcus species, n (%) | 48 (13.19) | 10 (8.62) | 38 (15.3) | |
| Enterobacter species, n (%) | 17 (4.67) | 2 (1.72) | 15 (6.05) | |
| Staphylococcus species, n (%) | 42 (11.54) | 12 (10.3) | 30 (12.1) | |
| Candida species, n (%) | 64 (17.58) | 23 (19.8) | 41 (16.5) | |
| Escherichia species, n (%) | 94 (25.82) | 30 (25.9) | 64 (25.8) | |
| Klebsiella species, n (%) | 53 (14.56) | 24 (20.7) | 29 (11.7) | |
| Pseudomonas species, n (%) | 33 (9.06) | 10 (8.62) | 23 (9.27) | |
| Burkholderia species, n (%) | 8 (2.20) | 1 (0.86) | 7 (2.82) | |
| Serratia species, n (%) | 5 (1.37) | 4 (3.45) | 1 (0.40) | |
| APACHE II, median [IQR] | 16 [11; 23] | 19 [14; 26] | 15 [9; 22] | <0.001 |
| SOFA score, median [IQR] | 5 [3; 9] | 9 [6; 13] | 4 [2; 7] | <0.001 |
| Anti-platelet drugs, n (%) | 69 (19.0) | 17 (14.7) | 52 (21.0) | 0.152 |
| Septic Shock, n (%) | 151 (41.5) | 68 (58.6) | 83 (33.5) | <0.001 |
| Vasopressor usage, n (%) | 100 (27.5) | 51 (44.0) | 49 (19.8) | <0.001 |
| Mechanical Ventilation usage, n (%) | 128 (35.2) | 57 (49.1) | 71 (28.6) | <0.001 |
| Extra-corporeal epuration, n (%) | 168 (39.3) | 104 (39.4) | 64 (40.7) | 0.717 |
| Mortality | ||||
| 28-day death, n (%) | 73 (20.1) | 36 (31.0) | 37 (14.9) | 0.001 |
| In hospital death, n (%) | 54 (14.8) | 29 (25.0) | 25 (10.1) | <0.001 |
Date expressed as mean (SD) or median(Q1-Q3) or number (percentage). PLT, Platelet; CCI, Charlson comorbidity index; WBC, White blood cells; PT, prothrombin time; APTT, activated partial thromboplatin time; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment score.